Shots:
- Samsung Bioepis & Epis NexLab have entered a research collaboration & license agreement with G2GBIO to develop novel therapeutics using proprietary microsphere-based sustained-release technology
- As per the deal, Samsung Bioepis will receive full licensing rights to a long-acting Semaglutide asset, an option to license another asset, & first negotiation rights for three additional assets, with financial terms undisclosed
- Epis NexLab will co-develop the long-acting microsphere drug delivery platform, leveraging G2GBIO’s proprietary technology to support the development of innovative therapies
Ref: Businesswire | Image: Samsung Bioepis, Epis NexLab & G2GBIO | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
